SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medical Care AG & Co. KGAA - FMS

NEW YORK, Jan. 9, 2017

The investigation concerns whether Fresenius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On January 7, 2017, Fresenius reported that its U.S. unit had received subpoenas from federal prosecutors seeking information on the Company's ties with the American Kidney Fund, a charity that helps patients pay for kidney dialysis. 

On this news, Fresenius stock has fallen as much as $3.09, or 7.26%, to $39.46 on January 9, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com